ClinicalTrials.gg
Not yet recruitingNCT06648525Updated Oct 18, 2024

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

A Phase 2 interventional study of Adebrelimab and Irinotecan liposomes in Intrahepatic Cholangiocarcinoma (Icc), sponsored by Harbin Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Harbin Medical University · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing lenvatinib in Cholangiocarcinoma — 20 open to participants now, 22 under way, 4 of them phase 3. lenvatinib · Cholangiocarcinoma.

Planned enrollment
11th of 33
68 · median 40
Started
2024
with 6 others
Phase 2
25 of 33
14 open now
Primary completion
2027-04
later than 13 of 21 live
Registered
24th of 33
by date
Lead sponsor
1 of 33
Harbin Medical University

Among the 33 studies testing lenvatinib in Cholangiocarcinoma, this one is the 11th largest by planned enrollment, is one of 7 that started in 2024, is one of 25 in phase 2, reaches primary completion later than 13 of the 21 other live ones, and was the 24th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

20 of the 33 studies testing lenvatinib in Cholangiocarcinoma are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing lenvatinib in Cholangiocarcinoma, or all of them as a file.
02

Study summary

This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).

Read the detailed description

This study plans to recruit 68 patients with unresectable ICC who have not received prior systematic treatment. The patients will be randomly divided into two groups. Group A: patients will receive adebrelimab+irinotecan liposomes+5-fluorouracil+calcium folinate+lenvatinib; Group B: patients will receive treatment with adebrelimab+irinotecan liposomes+5-fluorouracil+calcium folinate. The combination of irinotecan liposomes+5-fluorouracil+calcium folinate will be used 9 times (Q2W), and adebrelimab ± lenvatinib will be used until disease progression or medication for 2 years.

03

Conditions studied

  • Intrahepatic Cholangiocarcinoma (Icc)

Keywords

  • Adebrelimab
  • Irinotecan liposomes
  • Lenvatinib
  • Intrahepatic Cholangiocarcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 75 years old, male or female not limited;
  2. confirmed unresectable locally advanced or intrahepatic cholangiocarcinoma with measurable tumor lesions (meeting 1.1 criteria);
  3. Have not received systemic anti-tumor treatment in the past;
  4. Patients who relapse more than 6 months after curative surgery or after completion of therapy (chemotherapy and/or radiotherapy) meet the inclusion criteria;
  5. PS:0-1;
  6. Expected survival period ≥ 3 months;
  7. The main organ functions are normal, which meets the following criteria:
  1. Blood routine examination (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days): (Hb) ≥ 85 g/L; (ANC) ≥ 1.5 × 109/L; count (PLT) ≥ 80 × 109/L; 2) Biochemical examination: (ALT) and aspartate aminotransferase (AST) ≤ 5 × ; Serum total (TBIL) ≤ 3 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN or rate ≥ 50ml/min; 3) Coagulation function: (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN; 4) Doppler ultrasound evaluation: (LVEF) ≥ 50%; 8. Women of childbearing age must undergo a negative pregnancy test (β HCG) before starting treatment, and women and men of childbearing age (who have sexual relations with women of childbearing age) must agree to continuously use effective measures during the treatment period and for 6 months after the last treatment dose; 9. Patients with a history of and C can be included in the study, but active hepatitis B patients must start antiviral therapy before starting the study treatment; 10. Participants voluntarily join the study and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women, or those who have the ability to conceive but refuse to take measures;
  2. History of other malignant tumors within the past 5 years, excluding cervical carcinoma in situ or squamous cell carcinoma of the skin that has been adequately treated, or basal cell carcinoma of the skin that has been largely controlled;
  3. Merge other serious uncontrolled diseases (such as individuals with a history of difficult to control mental illness or severe intellectual or cognitive impairment; severe heart failure, angina pectoris, myocardial infarction, arrhythmia, etc.);
  4. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, and severe impairment of lung function;
  5. Suffering from active, known or suspected diseases. Subjects with hypothyroidism who only require hormone replacement therapy and those with skin diseases that do not require systemic treatment may be included;
  6. Easy to bleed, at risk of massive hemoptysis, and with a history of significant coagulation dysfunction;
  7. Suffering from hypertension and unable to achieve good control with antihypertensive medication (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg);
  8. History of immunodeficiency, including testing positive, having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation and bone marrow transplantation;
  9. Severe active infections requiring intravenous antibiotic treatment occur during the screening period;
  10. Individuals with multiple factors that affect oral medication (such as inability to swallow, post gastrointestinal resection, chronic diarrhea, and intestinal obstruction);
  11. Individuals who are allergic to the experimental drug;
  12. Patients who cannot comply with the trial protocol or cooperate with follow-up;
  13. The researchers believe that participants should not participate in this experiment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Group A: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate+lenvatinib

    Adebrelimab in combination with Irinotecan liposomes, 5-fluorouracil, calcium folinate and lenvatinib

    Drug: Adebrelimab · Drug: Irinotecan liposomes · Drug: Lenvatinib · Drug: 5-Fluorouracil (5-FU) · Drug: Calcium Folinate

  • Experimental
    Group B: Adebrelimab+Irinotecan liposomes+5-fluorouracil+calcium folinate

    Adebrelimab in combination with Irinotecan liposomes, 5-fluorouracil and calcium folinate

    Drug: Adebrelimab · Drug: Irinotecan liposomes · Drug: 5-Fluorouracil (5-FU) · Drug: Calcium Folinate

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free-Survival (PFS)

    The time from enrollment until tumor progression or death from any cause, whichever occurred first

    Time frame: up to 24 months

Secondary outcomes

  1. Objective response rate (ORR)

    The proportion of patients with a PR or CR, determined by RECIST v1.1 criteria

    Time frame: up to 24 months

  2. Disease control rate (DCR)

    The proportion of patients with a PR, CR, or SD

    Time frame: up to 24 months

  3. Overall survival (OS)

    The time calculated from enrollment until death from any cause, with living patients censored at the last known survival date

    Time frame: up to 24 months

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Incidence and severity of adverse events graded according to the NCI CTCAE v5.0.

    Time frame: up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Apr 2027, 30 months later.

Of 147 non-industry phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 30 months is below that.

Counting every sponsor, half of 173 studies reached it within 46 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Oct 18, 2024
StartEst.
Oct 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648525
Lead sponsor
Harbin Medical University
Responsible party
Zhiwei Li (Head of the gastroenterology ward, Harbin Medical University) — Principal investigator
First posted
Oct 18, 2024
Start date
Oct 2024 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 18, 2024

Study contacts

Zhiwei Li, MD
Contact
lzhw0451@163.com
86+15004683651

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Lenvatinib · Fluorouracil · Leucovorin

Start the discussion